| Literature DB >> 25944355 |
Nancy E Mayo1, Susan C Scott2, Charles N Bernstein3, Lisa M Lix4.
Abstract
BACKGROUND: As individuals experience changes in their health, they may alter the way they evaluate health and quality of life. The purpose of this study is to estimate the extent to which individuals with IBD change their rating of health over time because of response shift (RS).Entities:
Mesh:
Year: 2015 PMID: 25944355 PMCID: PMC4430902 DOI: 10.1186/s12955-015-0232-6
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Figure 1Flowchart of methods.
Characteristics of IBD cohort study participants (n = 388)
|
|
|
|
|
|---|---|---|---|
| Sex: (men/women) | 0 | 157/231 | 40%/60% |
| Age at baseline: Mean (SD) | 5 | 40.4 (14.5) | |
| <25/25–64/≥65 | 5 | 57/305/21 | 15%/80%/5% |
| Age at diagnosis: Mean (SD) | 9 | 36.0 (14.6) | |
| Diagnosis | 0 | ||
| Crohn’s | 187 | 48% | |
| Ulcerative colitis [ | 187 | 48% | |
| Indeterminate IBD | 14 | 4% | |
| Education: High School or less/Trade School or Diploma/University | 35 | 137/119/97 | 39%/34%/27% |
| Employment: | 6 | ||
| Working full time | 204 | 53% | |
| In school | 95 | 25% | |
| Working part-time | 34 | 9% | |
| Homemaker | 26 | 7% | |
| Retired | 20 | 5% | |
| Disabled | 3 | <1% | |
| Worked in last year | 7 | 313 | 82% |
| Missed work in last 6 months due to IBD | 37 | 116 | 33% |
[1] 18 of the 187 are indeterminate collitis.
SF-36 General health question (EVGGFP) at study entry and 2 years later among 289 (74%) with ratings at both measurement occasions
|
|
| ||
|---|---|---|---|
|
|
|
| |
| Excellent (12) | 4 (33.3%) | -- | 8 (66.7%) |
| Very good (90) | 48 (53.3%) | 10 (11.1%) | 32 (35.6%) |
| Good (116) | 64 (55.2%) | 28 (24.1%) | 24 (20.7%) |
| Fair (52) | 24 (46.2%) | 25 (48.1%) | 3 (5.8%) |
| Poor (19) | 4 (21.1%) | 15 (78.9%) | -- |
Proportions are row percents among persons at each of the five levels of outcome.
Disease activity, symptoms, functioning and social support at study entry and at one- and two-year follow-ups
|
|
|
|
| |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| ||||||
| General health perception [77] | 284 | 54.9 (21.3) | 357 | 53.0 (21.4) | 342 | 56.9 (22.3) |
| Physical function [86] | 335 | 81.0 (21.5) | 354 | 82.5 (21.8) | 345 | 83.2 (22.0) |
| Role physical [82] | 379 | 69.1 (29.0) | 357 | 75.2 (26.7) | 346 | 77.1 (25.1) |
| Bodily pain [76] | 351 | 58.3 (23.8) | 360 | 61.8 (21.7) | 348 | 62.7 (22.1) |
| Vitality [66] | 380 | 49.5 (20.8) | 359 | 51.8 (21.8) | 345 | 51.5 (22.8) |
| Social function [86] | 381 | 67.4 (27.9) | 358 | 79.5 (24.8) | 347 | 79.2 (23.3) |
| Role emotional [84] | 379 | 78.7 (23.1) | 360 | 83.0 (22.2) | 347 | 83.3 (21.2) |
| Mental health [78] | 379 | 67.6 (17.3) | 360 | 71.5 (17.3) | 345 | 71.7 (18.4) |
|
| ||||||
| Bowel symptoms | 364 | 5.3 (1.1) | 350 | 5.4 (1.1) | 343 | 5.5 (1.1) |
| Emotional health | 338 | 5.2 (1.1) | 354 | 5.4 (1.1) | 344 | 5.5 (1.0) |
| Social function | 346 | 5.9 (1.3) | 336 | 6.1 (1.3) | 336 | 6.2 (1.1) |
| Systemic symptoms | 365 | 4.4 (1.3) | 352 | 4.6 (1.3) | 344 | 4.7 (1.3) |
|
| ||||||
| Global | 381 | 13.7 (12.0) | 358 | 12.9 (12.1) | 351 | 12.2 (10.8) |
| Somatization | 379 | 17.2 (15.0) | 358 | 16.2 (15.6) | 351 | 14.8 (15.1) |
| Somatization excluding nausea | 379 | 15.9 (14.9) | 358 | 14.5 (15.2) | 351 | 13.6 (14.9) |
| Obsessive compulsive | 381 | 21.2 (18.1) | 358 | 21.2 (18.9) | 351 | 20.0 (16.4) |
| Sensitivity | 381 | 14.7 (17.6) | 358 | 13.4 (16.8) | 352 | 13.1 (16.0) |
| Depression | 381 | 15.6 (18.3) | 358 | 12.5 (16.5) | 352 | 12.9 (15.0) |
| Anxiety | 380 | 13.3 (14.6) | 358 | 12.8 (14.8) | 352 | 11.3 (13.0) |
| Hostility | 381 | 13.0 (13.9) | 358 | 11.8 (12.5) | 351 | 11.1 (11.8) |
| Phobic | 379 | 5.1 (10.6) | 358 | 5.1 (12.1) | 351 | 4.0 (9.0) |
| Paranoid | 380 | 9.4 (12.8) | 358 | 9.6 (13.8) | 352 | 9.9 (13.9) |
| Psychoticism | 381 | 7.0 (11.2) | 358 | 7.1 (11.0) | 351 | 7.6 (11.3) |
|
| ||||||
| Total | 341 | 66.2 (14.1 | 358 | 65.4 (16.1) | 349 | 65.7 (16.5) |
| Significant other (1–7) | 346 | 5.8 (1.5) | 358 | 5.8 (1.6) | 349 | 5.8 (1.6) |
| Family (1–7) | 374 | 5.6 (1.4) | 359 | 5.5 (1.5) | 351 | 5.5 (1.5) |
| Friends (1–7) | 375 | 5.2 (1.5) | 359 | 5.1 (1.5) | 351 | 5.1 (1.6) |
|
| ||||||
| CPSS total | 371 | 22.4 (8.2) | 356 | 21.4 (8.5) | 344 | 20.9 (8.7) |
Best predictive model of EVGGFP over time
|
|
|
|
|
|---|---|---|---|
| Active disease | Y/N | 0.242 (0.039) | <.0001 |
| IBDQ systemic | 0–6 | 0.070 (0.022) | 0.0014 |
| SF-36 vitality | 100–0 | 0.010 (0.001) | <.0001 |
| SF-36 pain | 100–0 | 0.006 (0.001) | <.0001 |
| BSI somatization* | 0–83.33 | 0.005 (0.002) | 0.0021 |
| BSI psychoticism | (30–85) vs (0–25) | 0.207 (0.070) | 0.0030 |
| SF-36 physical function | 100–0 | 0.008 (0.001) | <.0001 |
| IBDQ social function | 6.5 v 7 | 0.047 (0.043) | 0.2702 |
| 5.5–6.5 v 7 | 0.086 (0.049) | 0.0792 | |
| <4.5 v 7 | 0.133 (0.061) | 0.0295 |
Predictors modeled with lower as the better score and higher as worse. Gender was also included, as it explained variance, but only time-dependent variables contribute to the residuals that are modeled. BSI = Brief Symptom Inventory; IBDQ = Inflammatory Bowel Disease Questionnaire.
*excluding nausea/upset stomach.
Trajectory groups of RS categories
|
|
|
|
| |
|---|---|---|---|---|
| Theoretical% | 82.1 | 8.3 | 6.4 | 3.3 |
| N (%) based on assignment | 294 (81.9%) | 31 (8.6%) | 23 (6.4%) | 11 (3.1%) |
| Range of centered residuals | ||||
| Mean (SD) | 0.89 (0.34) | 2.00 (0.45) | 2.22 (0.59) | 2.03 (0.50) |
| Min-Max | 0.07–1.58 | 1.43–3.11 | 1.59–3.67 | 1.35–3.02 |
| Posterior probability of belonging to RS group (>0.7 considered good fit) | ||||
| Mean (SD) | 0.99 (0.04) | 0.92 (0.16) | 0.95 (0.11) | 0.93 (0.15) |
Modelled on 1,653 observations among 359 subjects with at least 3 outcomes at interviews with at least half the predictors.
Figure 2Four-trajectory model of response shift.
Figure 3Observed compared to expected health-related quality of life.
Figure 4Six-group model of EVGGFP.
Figure 5EVGGFP conditional on response shift from dual trajectory model.
Baseline predictors of response shift
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
| Age at diagnosis: older age at diagnosis reduces the risk of RS+ | - | 0.96 (0.93, <1.00) | 30 v 38 (14.8) p = 0.0216 | |
| BSI Hostility: more hostility symptoms (score ≥35) at baseline increases the risk of RS+ | 3.63 (1.11, 11.94) | 17% v 5% scored above 35 P = 0.0477^ | ||
|
| ||||
| GH: | - | |||
| Higher GH at baseline reduces risk of RS+ | 0.74 | 41.6 v 55.5 (21.5) p = 0.0072 | ||
| (0.59, 0.93) | ||||
| Pain: | ||||
| Lower pain at baseline reduces risk for RS- and RS+ | 0.86 | 51.1 v 60.3 (2.4) | 0.79 | 45.5 v 60.3 (24.9) p = 0.0080 |
| (0.74, 1.01) | p = 0.0593 | (0.66,0.95) | ||
| MH: | - | | | ||
| Better MH at baseline reduces risk of RS+ | 0.76 (0.60, 0.95) | 59.6 v 68.7 (17.3) p = 0.0152 | ||
| Social: | ||||
| Better social function at baseline reduces the risk of RS- and RS+ | 0.88 | 58.9 v 69.3 (27.7) p = 0.0465 | 0.87 | 57.6 v 69.3 (27.9) p = 0.0533 |
| (0.77, 1.00) | (0.75, 1.00) | |||
| RP: | - | |||
| Better role physical at base-line reduces the risk of RS+ | 0.87 (0.76,<1.00) | 56.8 v 70.1 (29.8) p = 0.0398 | ||
All comparisons are univariate ^using Fisher’s exact test.
CI: confidence interval.